Fig. 1: POLRMT upregulation in prostate cancer correlates with poor survival.

The Cancer Genome Atlas (TCGA) prostate cancer cohort (TCGA PRAD) shows POLRMT expression (RNA-Seq) in prostate cancer tissues (“Tumor”, n = 501) and normal prostate tissues (“Normal”, n = 52) (A). TCGA PRAD shows POLRMT expression in prostate cancer tissues (“Tumor”, n = 52) and matched adjacent normal prostate tissues (“Normal”, n = 52) (B). The Kaplan-Meier survival analyses show the association between POLRMT expression and the overall survival of total prostate cancer patients (C) and subgroup prostate cancer patients (E, F). The receiver operating characteristic (ROC) curve results demonstrated the relationship between POLRMT overexpression and the potential predictive effect on prostate cancer patients’ survival (D).